New chemo cocktail blocks breast cancer like a strong fence
First drug to aim at preventing spread of breast cancer to organs
A researcher from Northwestern University Feinberg School of Medicine has found a way to strengthen the breast's "fence" to prevent cancer from metastasizing. Researcher Seth Corey, M.D., has discovered that when a drug normally used to treat leukemia is added to a commonly used breast cancer drug, the potent new chemotherapy cocktail helps prevent breast cancer cells from invading.
"This is an entirely new way of targeting a cancer cell," said Corey, the Sharon B. Murphy-Steven T. Rosen Research Professor of Cancer Biology and Chemotherapy at the Feinberg School and director of the pediatric oncology program at the Robert H. Lurie Comprehensive Cancer Program of Northwestern University.
Working in the lab with women's breast cancer cells, Corey found that when the leukemia drug dasatinib is combined with the breast cancer drug doxorubicin, the potent mix inhibits breast cancer cell invasion by half. Corey is the principal investigator of the study, which recently was reported in the British Journal of Cancer .
Dasatinib targets an enzyme called the Src kinase, which is believed to play a key role in breast cancer invasion and metastases.
"Perhaps this drug could be given to prevent invasion from happening in the first place," said Corey, who also is a pediatric oncologist at Children's Memorial Hospital. "This might keep the disease in check and prevent it from progressing."
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.